Lack of somatic mutations in EGFR tyrosine kinase domain in hepatocellular and nasopharyngeal carcinoma

Pharmacogenetics and Genomics

Volumn 16, Issue 1, 2006, Pages 73-74

  Lee, Soo Chin ^a   Lim, Seng Gee ^a   Soo, Ross ^a   Hsieh, Wen Son ^b   Guo, Jia Yi ^a   Putti, Thomas ^a   Tao, Qian ^b,c   Soong, Richie ^a,d   Goh, Boon Cher ^a  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b Johns Hopkins Singapore   (Singapore)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

EGFR; EGFR mutations; EGFR tyrosine kinase inhibitors; Hepatocellular carcinoma; Nasopharyngeal carcinoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GENETICS; CONTROLLED STUDY; DRUG EFFECT; EXON; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; NASOPHARYNX CARCINOMA; PREVALENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; SOMATIC MUTATION;

ANIMALIA;

EID: 29144518064     PISSN: 17446872     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fpc.0000184959.82903.02     Document Type: Article

References (10)

1. Ito Y, Takeda T, Sakon M, Tsujimoto M, Higashiyama S, Noda K, et al. Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br J Cancer 2001; 84:1377-1383.
2. Leong JL, Loh KS, Putti TC, Goh BC, Tan LK. Epidermal growth factor receptor in undifferentiated carcinoma of the nasopharynx. Laryngoscope 2004; 114:153-157.
3. Matsuo M, Sakurai H, Saiki I. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, shows antimetastatic activity using a hepatocellular carcinoma model. Mol Cancer Ther 2003; 2:557-561.
4. Hopfner M, Sutter AP, Huether A, Schuppan D, Zeitz M, Scherubl H. Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma. J Hepatol 2004; 41:1008-1016.
5. Sun Y, Fry DW, Vincent P, Nelson JM, Elliott W, Leopold WR. Growth inhibition of nasopharyngeal carcinoma cells by EGF receptor tyrosine kinase inhibitors. Anticancer Res 1999; 19:919-924.
6. Zhu XF, Liu ZC, Xie BF, Li ZM, Feng GK, Yang D, et al. EGFR tyrosine kinase inhibitor AG1478 inhibits cell proliferation and arrests cell cycle in nasopharyngeal carcinoma cells. Cancer Lett 2001; 169:27-32.
7. Philip PA, Mahoney M, Thomas J, Pitot H, Donehower R, Kim G, et al. Phase II trial of erlotinib (OSI-774) in patients with hepatocellular or biliary cancer. Proc ASCO 2004; 22:319s.
8. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-2139.
9. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101:13306-13311.
10. Lee JW, Soung YH, Kim SY, Park WS, Nam SW, Lee JY, et al. Absence of EGFR mutation in the kinase domain in common human cancers besides non-small cell lung cancer. Int J Cancer 2005; 113:510-511.